VanEck Associates’s Aevi Genomic Medicine, Inc. GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-17,054
| Closed | -$21K | – | 731 |
|
|
2017
Q3 | $21K | Buy |
17,054
+761
| +5% | +$937 | ﹤0.01% | 722 |
|
|
2017
Q2 | $22K | Buy |
16,293
+1,846
| +13% | +$2.49K | ﹤0.01% | 731 |
|
|
2017
Q1 | $27K | Hold |
14,447
| – | – | ﹤0.01% | 867 |
|
|
2016
Q4 | $75K | Sell |
14,447
-1,299
| -8% | -$6.74K | ﹤0.01% | 757 |
|
|
2016
Q3 | $88K | Buy |
15,746
+58
| +0.4% | +$324 | ﹤0.01% | 732 |
|
|
2016
Q2 | $87K | Sell |
15,688
-4,295
| -21% | -$23.8K | ﹤0.01% | 702 |
|
|
2016
Q1 | $88K | Buy |
19,983
+115
| +0.6% | +$506 | ﹤0.01% | 687 |
|
|
2015
Q4 | $120K | Buy |
19,868
+2,279
| +13% | +$13.8K | ﹤0.01% | 605 |
|
|
2015
Q3 | $138K | Buy |
17,589
+2,248
| +15% | +$17.6K | ﹤0.01% | 597 |
|
|
2015
Q2 | $94K | Sell |
15,341
-1,520
| -9% | -$9.31K | ﹤0.01% | 657 |
|
|
2015
Q1 | $136K | Sell |
16,861
-1,206
| -7% | -$9.73K | ﹤0.01% | 623 |
|
|
2014
Q4 | $91K | Buy |
18,067
+3,198
| +22% | +$16.1K | ﹤0.01% | 648 |
|
|
2014
Q3 | $77K | Buy |
14,869
+1,382
| +10% | +$7.16K | ﹤0.01% | 662 |
|
|
2014
Q2 | $105K | Buy |
13,487
+2,363
| +21% | +$18.4K | ﹤0.01% | 677 |
|
|
2014
Q1 | $78K | Buy |
11,124
+2,308
| +26% | +$16.2K | ﹤0.01% | 667 |
|
|
2013
Q4 | $53K | Buy |
+8,816
| New | +$53K | ﹤0.01% | 664 |
|